NPM1 and acute myeloid leukemia: Leukemia-specific assays targeting stable genetic lesions, such as NPM1 mutations, PML-RARA and core-binding factor (CBF) rearrangements, or other recurrent fusions, enable sensitive detection of residual disease in certain genetically defined AML subtypes (Heuser et al., 2021).